
|Articles|April 22, 2015
- Melanoma (Issue 4)
- Volume 4
- Issue 1
Comparing Two Doses of Ipilimumab
Author(s)Ahmad Tarhini, MD, PhD
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).
Advertisement
Ahmad Tarhini, MD, PhD, associate professor, University of Pittsburgh School of Medicine, compares two doses of ipilimumab (Yervoy).
<<<
Articles in this issue
over 10 years ago
Toxicity of Immunotherapies in Melanomaover 10 years ago
New Standards Needed to Lessen Surgery Delays in Melanomaover 10 years ago
Gene Removal May Pose Future Treatment in Advanced Melanomaover 10 years ago
The Development of T-VEC for Melanomaover 10 years ago
The Role of Macrophages in BRAF Inhibitor ResistanceAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
3
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5







































